Milestone Pharmaceuticals (MIST)
(Delayed Data from NSDQ)
$1.92 USD
-0.03 (-1.54%)
Updated Sep 19, 2025 04:00 PM ET
After-Market: $1.92 0.00 (0.00%) 7:58 PM ET
3-Hold of 5 3
F Value D Growth B Momentum F VGM
Fundamental Charts
About Price to Cash Flow
The Price to Cash Flow ratio or P/CF is price divided by its cash flow per share. It's another great way to determine whether a company is undervalued or overvalued with the denominator being cash flow. One of the reasons why some investors prefer the P/CF ratio over the P/E ratio is because the net income of the cash flow portion rightly adds depreciation and amortization back in since these are not cash expenditures. In contrast, the net income that goes into the earnings portion of the P/E ratio does not add these in, thus artificially reducing the income and skewing the P/E ratio. Like the P/E ratio, a lower number is considered better. A value under 20 is generally considered good.
MIST 1.92 -0.03(-1.54%)
Will MIST be a Portfolio Killer in September?
Zacks Investment Research is releasing its prediction for MIST based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for MIST
Milestone Pharmaceuticals (MIST) Upgraded to Buy: Here's Why
MIST Stock Falls 66% Following Complete Response Letter for Cardamyst
MIST: What are Zacks experts saying now?
Zacks Private Portfolio Services
After Golden Cross, Milestone Pharmaceuticals (MIST)'s Technical Outlook is Bright
Other News for MIST
Is MIST coiling for a breakout? NR7 shows up after advancing 0.52%
MIST forms Upper Bollinger Band Walk on September 17
MIST forms Death Cross on September 16
Is MIST signaling a buying opportunity? New Uptrend shows up after advancing 0.51%
Analysts Offer Insights on Healthcare Companies: Kala Pharmaceuticals (KALA) and Milestone Pharmaceuticals (MIST)